CTCBIO (A060590) Stock Overview
Provides various pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A060590 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CTCBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,715.00 |
| 52 Week High | ₩7,910.00 |
| 52 Week Low | ₩4,580.00 |
| Beta | -0.079 |
| 1 Month Change | -8.80% |
| 3 Month Change | -20.62% |
| 1 Year Change | -30.66% |
| 3 Year Change | -22.96% |
| 5 Year Change | -38.61% |
| Change since IPO | -7.52% |
Recent News & Updates
These 4 Measures Indicate That CTCBIO (KOSDAQ:060590) Is Using Debt Reasonably Well
Dec 02
Some Shareholders Feeling Restless Over CTCBIO Inc.'s (KOSDAQ:060590) P/S Ratio
Sep 29Recent updates
These 4 Measures Indicate That CTCBIO (KOSDAQ:060590) Is Using Debt Reasonably Well
Dec 02Some Shareholders Feeling Restless Over CTCBIO Inc.'s (KOSDAQ:060590) P/S Ratio
Sep 29CTCBIO's (KOSDAQ:060590) Shareholders Are Down 64% On Their Shares
Mar 15Is CTCBIO (KOSDAQ:060590) Using Too Much Debt?
Jan 21
Would Shareholders Who Purchased CTCBIO's (KOSDAQ:060590) Stock Five Years Be Happy With The Share price Today?
Nov 29Shareholder Returns
| A060590 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 2.3% | 1.1% | 4.3% |
| 1Y | -30.7% | 22.8% | 71.1% |
Return vs Industry: A060590 underperformed the KR Pharmaceuticals industry which returned 22.8% over the past year.
Return vs Market: A060590 underperformed the KR Market which returned 71.1% over the past year.
Price Volatility
| A060590 volatility | |
|---|---|
| A060590 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A060590 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A060590's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 245 | Sun Cho Chang | www.ctcbio.com |
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19.
CTCBIO Inc. Fundamentals Summary
| A060590 fundamental statistics | |
|---|---|
| Market cap | ₩112.73b |
| Earnings (TTM) | ₩2.65b |
| Revenue (TTM) | ₩132.76b |
Is A060590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A060590 income statement (TTM) | |
|---|---|
| Revenue | ₩132.76b |
| Cost of Revenue | ₩78.86b |
| Gross Profit | ₩53.90b |
| Other Expenses | ₩51.25b |
| Earnings | ₩2.65b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 110.83 |
| Gross Margin | 40.60% |
| Net Profit Margin | 2.00% |
| Debt/Equity Ratio | 47.7% |
How did A060590 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/03 09:53 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CTCBIO Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| JongHoon Lee | Daishin Securities Co. Ltd. |
| Al Eum Lee | iM Securities |
| Jae Hoon Shin | LS Securities Co., Ltd. |